Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 202-860-4 | CAS number: 100-52-7
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: inhalation
Administrative data
- Endpoint:
- short-term repeated dose toxicity: inhalation
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Study performed in accordance with OECD guideline 412. However, summary in public literature available, no summary and individual data of all results available.
Data source
Reference
- Reference Type:
- publication
- Title:
- Unnamed
- Year:
- 1 991
Materials and methods
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 412 (Subacute Inhalation Toxicity: 28-Day Study)
- Deviations:
- yes
- Remarks:
- No analytical results available, however, analysis of test concentrations was performed.
- GLP compliance:
- not specified
- Limit test:
- no
Test material
- Reference substance name:
- Benzaldehyde
- EC Number:
- 202-860-4
- EC Name:
- Benzaldehyde
- Cas Number:
- 100-52-7
- Molecular formula:
- C7H6O
- IUPAC Name:
- benzaldehyde
- Details on test material:
- Batch No.: not specified
Purity: 98+% pure
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Sprague-Dawley (SD)
- Weight at study initiation: 184±2 g for females and 240±2 g for males
- Housing: Animals were individually identified with ear notches and randomly assigned by a computer-assisted method that provided homogeneity of variance and equality of initial body weights for all groups.
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22±1°C
- Humidity (%): 50%±15%
No additional data
Administration / exposure
- Route of administration:
- inhalation: vapour
- Type of inhalation exposure:
- whole body
- Vehicle:
- clean air
- Remarks on MMAD:
- MMAD / GSD: Not applicable. Animals were exposed to vapour.
- Details on inhalation exposure:
- GENERATION OF TEST ATMOSPHERE / CHAMBER DESCRIPTION
- Exposure apparatus: Sage Instrument co. syringe pump (model 220).
- Method of holding animals in test chamber: Animals were exposed in 2.50 m3 stainless steel chambers.
- Air flow rate: 500 L/min
TEST ATMOSPHERE
- Brief description of analytical method used: gas chromatography
- Samples taken from breathing zone: yes
No additional data - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- The inhalation chambers were continuously monitored throughout the exposure by gas chromatography. Concentration of the test substance in air was deteremined for each chamber every 6 minutes by using an automatic sampling system and a Bendix gas chromatograph. The monitory was conducted by comparion with a standard sample chromatographed on a CSP-20M stainless steel column under the following conditions: injector and electron capture detector temperature, 175°C, oven temperature, 100°C, flow rate for the carrier gas nitrogen, 120mL/min, hydrogen, 32.3 mL/min, and air: 300 mL/min. The retention time of the test substance was found to be 260 seconds.
- Duration of treatment / exposure:
- Animals were exposed for 6 hours/day for 14 days.
- Frequency of treatment:
- Animals were exposed for 14 consecutive days.
Doses / concentrations
- Remarks:
- Doses / Concentrations:
0, 500, 750 and 1000 ppm
Basis:
no data
- No. of animals per sex per dose:
- 14 animals/sex/concentration
- Control animals:
- yes
- Details on study design:
- The study was performed in accordance with OECD guideline 412.
Rats from the control and each test substance exposure group were necropsied 72 hours after the last exposure. - Positive control:
- No positive control was included.
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: daily
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: daily
BODY WEIGHT: Yes
- Time schedule for examinations: after 2, 8 and 14 exposures
FOOD CONSUMPTION:
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: No data
FOOD EFFICIENCY:
- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted averages from the consumption and body weight gain data: No data
WATER CONSUMPTION: No data
OPHTHALMOSCOPIC EXAMINATION: No data
HAEMATOLOGY: Yes
- Time schedule for collection of blood: Blood samples were taken at necropsy from the vena cava.
- Anaesthetic used for blood collection: No data
- Animals fasted: No data
- How many animals: 6
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: Blood samples were taken at necropsy from the vena cava.
- Animals fasted: No data
- How many animals: 6
URINALYSIS: No data
NEUROBEHAVIOURAL EXAMINATION: No data
OTHER:
No additional data - Sacrifice and pathology:
- At necropsy, a gross pathological examination was performed on all animals. The rats found moribund after exposure were immediately necropsied to prevent autolysis of tissues. Seven animals/sex/dose were necropsied 72 hours after the last exposure, the remaining animals were subjected to whole body perfusion and prepared for future electron microscopy examination.
The following tissues were excised and collected for histopathological examination: adrenals, brain, heart, kidneys, liver, lungs, small and large intestines, larynx, rhinopharynx, spleen, stomach, trachea, testes or ovaries, thyroid and urinary bladder. The following organs were weighed prior to perfusion: brain, heart, kidneys, livers, lungs and spleen.
During necropsy, special care was taken to avoid damage to the brain and nasal tissues. Tisses were fixed, processed, and embedded in paraffin, sectionated at 6 µm, stained with hematoxy and eosin, and examined by light microscopy.
Nasal tissues of 7 animals of the control, 500 and 1000 ppm groups were first declacified in a formin acid-sodium citrate solution before processing and embedding. Sections were cut to illustrate the respiratory, olfactory and stratified squamous eptihelia. - Other examinations:
- Heamatology and clinical biochemistry was performed in 6 animals of the control, 500 and 750 ppm groups and 4 animals of the 1000 ppm group. Blood was taken at necropsy (no time after last exposure indicated).
The following haematological parameters were determined: red blood cell count, white blood cell count, hematocrit, mean corpuscular volume, hemoglobin, mean corpuscular hemoglobin and mean corpuscular hemoglobin concentration.
Acetylcholinesterase was determined in red cells, and the following biochemical parameters were determined in serum: albumin, bilirubin, blood urea nitrogen, cholesterol, glucose, inorganic phosphorus, total protein, triglycerides, calcium, chloride, magnesium, potassium, sodium, amylase, cholinesterase, creatine phophokinase, gamma-glutamyl transferase, aspartate aminotransferase, alanine aminotransferase, alpha-hydroxybutyrate dehydrogenase and alkaline phosphatase. - Statistics:
- Body and tissue weights and hematology, biochemistry and physiological data were analyzed using a one-way analysis of variance, Duncan's multiple range test, and a modified least significant difference procedure. For parameters fuond to be significantly different (p≤0.05). Student's t-test was used to determine levels of significance between groups.
Results and discussion
Results of examinations
- Clinical signs:
- effects observed, treatment-related
- Mortality:
- mortality observed, treatment-related
- Body weight and weight changes:
- effects observed, treatment-related
- Food consumption and compound intake (if feeding study):
- not specified
- Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- not specified
- Ophthalmological findings:
- not specified
- Haematological findings:
- effects observed, treatment-related
- Clinical biochemistry findings:
- effects observed, treatment-related
- Urinalysis findings:
- not specified
- Behaviour (functional findings):
- effects observed, treatment-related
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Gross pathological findings:
- no effects observed
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Histopathological findings: neoplastic:
- no effects observed
- Details on results:
- CLINICAL SIGNS AND MORTALITY
Clinical signs (incl. signs of neurotoxicity e.g. reduced motor activity) and hypothermia in all test substance exposed groups. Mortality at 750 and 1000 ppm. Nasal and ocular irritatation in all test substance exposed groups.
BODY WEIGHT AND WEIGHT GAIN
Reduced weight gain in all test substance exposed males and 1000 ppm females.
HAEMATOLOGY
Increase in monocytes in all test females, slightly reduced red blood cell count, hemoglobin and hematocrit in 1000 ppm females. Increased white blood cell count and neurophils in males at 1000 ppm, a slightly reduced hemaglobin and hematocrit in males at 1000 ppm. A decrease in lymphocytes, mean corpuscular hemoglobin and mean corpuscular hemoglobin concentration at 750 and 1000 ppm.
CLINICAL CHEMISTRY
Reduced serum ChE in all test females. An increased in ASAT in all test males and females. A decrease in albumin and total protein in all test females.
NEUROBEHAVIOUR
Tremors, piloerection, diuresis, reduction of breathing rate in all test groups. Animals at 750 and 1000 ppm were extreme sensitive to noise in the room and displayed aggressive behaviour.
ORGAN WEIGHTS
Increase in absolute and relative liver weight in all female test groups.
GROSS PATHOLOGY
No findings.
HISTOPATHOLOGY: NON-NEOPLASTIC
Goblet cell metaplasia was seen in all treated males: 4/7 at 500, 750 and 1000 ppm. The goblet cell metaplasia was extensive in the respiratory epithelial lining of the septum, but was minimal in the epithelial lining of the turbinates. The overall change in males was considered mild. Similar, less frequent changes were observed in females. Besides the goblet cell metaplasia, no inflammatory, degenerative, or other alterations were observed in the nasal tissues. Findings in other organs were infrequent and appeared to be incidental background changes regularly observed in this strain of rat.
No additional data
Effect levels
- Dose descriptor:
- LOAEC
- Effect level:
- 500 ppm
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: Physiological monitoring, clinical observations, organ weights.
Target system / organ toxicity
- Critical effects observed:
- not specified
Applicant's summary and conclusion
- Conclusions:
- In a subacute inhalation study in rats, a NOAEC could not be derived, since effects of the test substance were noted in all treatment groups. Clinical observations (indicative of neurotoxicity), hypothermia and goblet cell metaplasia were noted at concentrations of 500 ppm and above. Therefore, the LOAEC for systemic and local effects is established at 500 ppm (equivalent to 2.2 mg/L).
- Executive summary:
This study was run according to a guideline which is equivalent or similar to OECD Guideline 412 with Sprague-Dawley rat. The clinical signs, mortality, body weight, haematology, clinical chemistry, neurobehaviour,organ weights, gross pathology and non-neoplastic histopathology were observed.
In a subacute inhalation study in rats, a NOAEC could not be derived, since effects of the test substance were noted in all treatment groups. Clinical observations (indicative of neurotoxicity), hypothermia and goblet cell metaplasia were noted at concentrations of 500 ppm and above. Therefore, the LOAEC for systemic and local effects is established at 500 ppm (equivalent to 2.2 mg/L).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.